惠陶集團(08238.HK):於11月30日向聯交所提交一份復牌計劃
格隆匯 12 月 7日丨惠陶集團(08238.HK)宣佈,公司於2020年11月30日向聯交所提交一份復牌計劃。復牌計劃載列業務發展計劃及其他重要資料,包括證明其擁有可行及可持續業務的溢利預測及遵照GEM上市規則第17.26條。集團一直實行業務發展計劃,用以促使業務恢復至充份及可持續的水平,包括但不限於(i)積極獲取新合約以保持增長勢頭;(ii)實施提高盈利能力的措施;(iii)實行擴展廣告牌業務、廣告策劃代理業務以及設計及製作業務的策略以分散整體業務風險;(iv)實施嚴格的成本控制措施;及(v)實施監控措施以儘量減低新冠狀病毒爆發的影響。
此外,公司股份繼續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.